The development of antiretroviral therapy for the prevention and treatment of HIV infection
has been marked by a series of remarkable successes. However, the efforts to develop a …

Antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV transmission was first
approved by the US Food and Drug Administration in 2012. Despite correlations of …

Background Oral pre-exposure prophylaxis has been introduced in more than 70 countries,
including many in sub-Saharan Africa, but women experience considerable barriers to daily …

Background Safe and effective long-acting injectable agents for preexposure prophylaxis
(PrEP) for human immunodeficiency virus (HIV) infection are needed to increase the options …

Background Tenofovir alafenamide shows high antiviral efficacy and improved renal and
bone safety compared with tenofovir disoproxil fumarate when used for HIV treatment. Here …

Oral antiretroviral agents provide life-saving treatments for millions of people living with HIV,
and can prevent new infections via pre-exposure prophylaxis,,,–. However, some people …

HIV Preexposure Prophylaxis, by Race and Ethnicity — United States, 2014–2016 | MMWR Skip
directly to site content Skip directly to page options Skip directly to AZ link Centers for Disease …

Background There are few data available regarding the use of on-demand pre-exposure
prophylaxis (PrEP) for HIV prevention. We aimed to assess PrEP effectiveness, adherence …

Objective To conduct a systematic review and meta-analysis of randomised controlled trials
(RCTs) of the effectiveness and safety of oral pre-exposure prophylaxis (PrEP) to prevent …

Global trends in HIV infection demonstrate an overall increase in HIV prevalence and
substantial declines in AIDS related deaths largely attributable to the survival benefits of …